Get emailed when ASND changes direction
Factor Model (net -3.0)
Factor Model
net -3.0
Est. Revisions
-0.9
Insider Activity
+0.0
Momentum
+0.0
Analyst Rev.
-1.0
Narrative Gap
+0.0
Analysis pending — waiting for first signal cycle.
Evidence
5d ago
B of A Securities main ASND: Buy → Buy
17d ago
Ascendis Pharma A/S (ASND) Reports Positive Week 52 Data from Phase 2 New InsiGHTS Trial
yahoo-finance
Fundamentals & Data ▾
Ascendis Pharma A/S
Healthcare · Biotechnology
Mkt Cap
$15B
Beta
0.48
52w Range
$150.89 - $250.74
Short Interest
3.7M 7.22%
Days to Cover
6.5 -4%
Technicals
downtrend
from 52w Hi
-3.8%
1w return
-3.8%
Analysts
mixed
EPS Estimate
$0.23
0up / 0dn
Est. Dispersion
0%
1 analysts
Analyst Target
$341
$341 - $341
Options P/C
0.04
Fund Convergence
strong
D.E. Shaw, Citadel, Two Sigma
Financials
Revenue
$248M +42% YoY
FCF
$70M
Gross Margin
90%
Op Margin
3%
Momentum:
decelerating
Top Holders
D.E. Shaw
$379M
Citadel
$128M
Two Sigma
$10M
4 signals · latest 5d ago
Get alerted when ASND changes direction
We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.